share_log

Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12

Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12

Wedbush以跑贏大盤的評級啓動對Prime Medicine的保險,宣佈目標股價爲12美元
Moomoo 24/7 ·  04/02 16:24

Wedbush analyst David Nierengarten initiates coverage on Prime Medicine (NASDAQ:PRME) with a Outperform rating and announces Price Target of $12.

Wedbush分析師戴維·尼倫加滕以跑贏大盤的評級啓動了對Prime Medicine(納斯達克股票代碼:PRME)的報道,並宣佈目標股價爲12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論